Compare NMG & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NMG | IRWD |
|---|---|---|
| Founded | 2011 | 1998 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Other Metals and Minerals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 671.4M | 663.6M |
| IPO Year | 2015 | 2009 |
| Metric | NMG | IRWD |
|---|---|---|
| Price | $1.91 | $3.58 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 3 |
| Target Price | $5.75 | ★ $7.67 |
| AVG Volume (30 Days) | 946.2K | ★ 2.2M |
| Earning Date | 05-13-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1400.00 |
| EPS | N/A | ★ 0.24 |
| Revenue | N/A | ★ $298,276,000.00 |
| Revenue This Year | N/A | $57.95 |
| Revenue Next Year | N/A | $4.39 |
| P/E Ratio | ★ N/A | $15.23 |
| Revenue Growth | N/A | ★ 8.88 |
| 52 Week Low | $1.60 | $0.55 |
| 52 Week High | $6.06 | $5.78 |
| Indicator | NMG | IRWD |
|---|---|---|
| Relative Strength Index (RSI) | 40.72 | 39.56 |
| Support Level | $1.81 | $3.07 |
| Resistance Level | $2.00 | $3.92 |
| Average True Range (ATR) | 0.11 | 0.33 |
| MACD | -0.02 | -0.11 |
| Stochastic Oscillator | 25.56 | 7.45 |
Nouveau Monde Graphite Inc is a mineral exploration company. The company specializes in the exploration, evaluation, and development of mineral properties located in Quebec and is developing a natural graphite-based anode material that would qualify as battery-grade material to supply the lithium-ion industry. The Company currently operates in two segments: the Mining projects (which includes the Matawinie Mine project and the Uatnan Mining Project) and the Battery Material Plant project.
Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.